ATP2A3

Across TCGA pan-cancer cohorts, ATP2A3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATP2A3 data layer compared with 28 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ATP2A3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ATP2A3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where ATP2A3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.991	0.402	.001	15	view →
CCRCC	OS	Quartile	III,IV	0.987	0.745	.006	2	view →
HNSC	OS	Quartile	II,III,IV	0.935	1.000	.042	2	view →
LUAD	DFS	Median	II,III,IV	0.628	0.376	.038	2	view →
LSCC	DFS	Tertile	All	0.852	0.448	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ATP2A3–PDAC (DFS)

Open the PDAC breakdown →